Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer
This was a randomized, multi centre, open label, two treatment, two period, two sequence, single dose, crossover study, with at least 28 days washout between doses, conducted under fed (normal breakfast) conditions.
Breast Cancer and Ovarian Cancer
DRUG: SPARC-08-038|DRUG: Ref-08-038
Maximum measured plasma concentration, 336 hours
The area under the plasma concentration versus time curve from time 0 to infinity, 336 hours
This was a randomized, multi centre, open label, two treatment, two period, two sequence, single dose, crossover study, with at least 28 days washout between doses, conducted under fed (normal breakfast) conditions.